By Michael Erman NEW YORK, Aug 13 (Reuters) - Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like .
Pushing back on the concept that there can only be one victor among branded obesity drugmakers, Novo Nordisk CEO Mike Doustdar thinks that investors aren’t seeing the whole picture.
Here’s what BMI is, when it’s useful, where it falls short and what else to pay attention to.
There's no shortage of weight-loss advice on social media, TikTok, television and AI chatbots.
People age at different speeds.
Obesity treatment can include GLP-1 medications, non-surgical procedures such as ESG stomach tightening and short-term gastric balloons, and traditional bariatric surgery.
Global obesity headlines almost always point in one direction: rising numbers, ballooning health costs, and countries where more than a third of adults now qualify as obese.
Obesity rates severely increased between 1990 and 2022 while rates of underweight people decreased in most countries, according to a new study, and the researchers believe access to more nutritious .
A narrative review found obesity independently worsens psoriasis severity and blunts response to fixed-dose biologics, prompting calls for weight-adapted treatment selection.
But data have started to emerge demonstrating that an overlooked but equal driver: the father, whose genetics, habits, and environment shape child obesity risk from preconception to postconception and .
Obesity is a global health concern that can contribute to diabetes, cardiovascular disease and other metabolic disorders.
Around seven million more adults are living with obesity than would have been if obesity rates had stayed the same as 1993.